Cowen Anticipates Dynavax’s Now-Approved Heplisav Will Lead the HBV Vaccine Market

Dynavax Technologies (NASDAQ:DVAX) after five years of “torturous” waiting has at long last garnered FDA approval for Heplisav-B. Cowen analyst Phil Nadeau anticipates hundreds of millions of dollars to be made in the HBV vaccine market within 5 years.

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts